Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00320
|
|||||
| Drug Name |
Ceftizoxime
|
|||||
| Synonyms |
(6R,7R)-7-(2-(2-Amino-4-thiazolyl)-2Z-(methoxyimino)acetamido)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carbonsaeure; (6R,7R)-7-(2-(2-Amino-4-thiazolyl)glyoxyamido)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-carbonsaeure-7-(Z)-(O-methyloxim); (6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(methyloxy)imino]acetyl}amino)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-2,3-didehydropenam-2-carboxylic acid; Cefizox (TN); Ceftix; Ceftizoxima; Ceftizoxima[INN-Spanish]; Ceftizoxime (INN); Ceftizoxime Monosodium Salt; Ceftizoxime [INN:BAN]; Ceftizoximum; Ceftizoximum [INN-Latin]; Eposerin; FK-749; FK749; FR 13749; FR-13479; FR-13749; SK&F 88373-2; SKF-88373; Syn-7-(2-(2-Amino-4-thiazolyl)-2-methoxyiminoacetamido)-3-cephem-4-carboxylic acid
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Gram-positive & negative bacteria infections [ICD11:1A00-1H0Z] | Approved | [1] | |||
| Therapeutic Class |
Antibiotics
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C13H13N5O5S2
|
|||||
| Canonical SMILES |
CON=C(C1=CSC(=N1)N)C(=O)NC2C3N(C2=O)C(=CCS3)C(=O)O
|
|||||
| InChI |
InChI=1S/C13H13N5O5S2/c1-23-17-7(5-4-25-13(14)15-5)9(19)16-8-10(20)18-6(12(21)22)2-3-24-11(8)18/h2,4,8,11H,3H2,1H3,(H2,14,15)(H,16,19)(H,21,22)/b17-7-/t8-,11-/m1/s1
|
|||||
| InChIKey |
NNULBSISHYWZJU-LLKWHZGFSA-N
|
|||||
| CAS Number |
CAS 68401-81-0
|
|||||
| Pharmaceutical Properties | Molecular Weight | 383.4 | Topological Polar Surface Area | 201 | ||
| Heavy Atom Count | 25 | Rotatable Bond Count | 5 | |||
| Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 10 | |||
| XLogP |
0
|
|||||
| PubChem CID | ||||||
| PubChem SID |
103174922
,114606946
,11641637
,124766423
,131323579
,134222601
,134337748
,135009953
,137006383
,140396425
,160870913
,160964629
,162178763
,170505879
,175268604
,179150929
,223678791
,226423279
,249865495
,251912547
,251916656
,252817575
,43181664
,46505647
,48415732
,49847130
,50050951
,50236104
,51091962
,57370867
,602886
,7978886
,87256558
,9107
|
|||||
| ChEBI ID |
CHEBI:553473
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | MRP4 | Transporter Info | Multidrug resistance-associated protein 4 | Substrate | [2] | |
| OAT1 | Transporter Info | Organic anion transporter 1 | Substrate | [3] | ||
| OAT3 | Transporter Info | Organic anion transporter 3 | Substrate | [4] | ||
| Drug-Transporter Activity Data | ||||||
| Drug-Transporter Activity Data | MRP4 | Transporter Info | Km =18 microM | Human embryonic kidney cells (HEK293)-MRP4 | [2] | |
| References | ||||||
| 1 | Ceftizoxime was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Oral availability of cefadroxil depends on ABCC3 and ABCC4. Drug Metab Dispos. 2012 Mar;40(3):515-21. | |||||
| 3 | FDA Drug Development and Drug Interactions | |||||
| 4 | Human organic anion transporter hOAT3 is a potent transporter of cephalosporin antibiotics, in comparison with hOAT1. Biochem Pharmacol. 2005 Oct 1;70(7):1104-13. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.